Dermelix Biotherapeutics
PrivateCompany Overview
Dermelix Biotherapeutics operates in Healthcare & Life Sciences and is based in New York City, New York. It was founded in 2018.
Dermelix Biotherapeutics is a biotechnology company that develops innovative therapies for rare and debilitating dermatologic conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Dermelix Biotherapeutics Comparables
Compare Dermelix Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Quoin Pharmaceuticals | 85% | |
| Azitra, Inc. | 83% | |
| ResVita Bio | 83% |
For institutional investors. Book with your work email.
Dermelix Biotherapeutics Funding Rounds
Historical fundraising activity
Dermelix Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Dermelix Biotherapeutics's valuation, stock price, and market status.
Is Dermelix Biotherapeutics a public or private company?
Dermelix Biotherapeutics is a private company.
What is the current stock price of Dermelix Biotherapeutics?
Dermelix Biotherapeutics is a private company, so its shares have no public market price. Caplight tracks Dermelix Biotherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Dermelix Biotherapeutics worth (valuation)?
Valuation information for Dermelix Biotherapeutics is not publicly available.
Can I buy Dermelix Biotherapeutics stock?
Dermelix Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Dermelix Biotherapeutics's last funding round?
Funding round information for Dermelix Biotherapeutics is not publicly available.
Who are the main investors in Dermelix Biotherapeutics?
Investor information for Dermelix Biotherapeutics is not publicly disclosed.
Will Dermelix Biotherapeutics IPO soon?
No public IPO plans have been announced for Dermelix Biotherapeutics.
How can I track Dermelix Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Dermelix Biotherapeutics's shares on secondary markets.